Black patients with triple-negative breast cancer may be less likely to receive immunotherapy than white patients
In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...
Mena FN1d
How Critical Demand For Metastatic Breast Cancer Therapies Is Producing A Multi-Billion Dollar Opportunity For Biotechs - Financial News Media
has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative ...
TMCnet2d
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
Oncolytics Biotech Reports Favorable Results For Breast Cancer Study
(RTTNews) - Clinical-stage company Oncolytics Biotech Inc. (ONCY), Thursday announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+ ...
Cancer Research2d
About the Journal
Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...
Cancer Research3d
About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...
Medscape3d
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
biopharma-reporter3d
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...
Pharmabiz3d
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...